tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

EXEL Stock Latest News

Exelixis price target raised to $43 from $42 at Truist
The FlyExelixis price target raised to $43 from $42 at Truist
4d ago
EXEL
Exelixis upgraded to Overweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Exelixis upgraded to Overweight from Equal Weight at Morgan Stanley
4d ago
EXEL
Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001
PremiumThe Fly
Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001
5d ago
EXEL
Exelixis reports on subgroup analysis of Phase 3 CABINET study
PremiumThe Fly
Exelixis reports on subgroup analysis of Phase 3 CABINET study
7d ago
EXEL
Exelixis downgraded to Perform from Outperform at Oppenheimer
PremiumThe Fly
Exelixis downgraded to Perform from Outperform at Oppenheimer
7d ago
EXEL
Exelixis downgraded to Perform at Oppenheimer on zanzalintinib concerns
PremiumThe FlyExelixis downgraded to Perform at Oppenheimer on zanzalintinib concerns
7d ago
EXEL
Jefferies has two ‘contradictory’ conclusions after Exelixis abstract release
Premium
The Fly
Jefferies has two ‘contradictory’ conclusions after Exelixis abstract release
9d ago
EXEL
Exelixis falls after ASCO releases colorectal cancer data
Premium
The Fly
Exelixis falls after ASCO releases colorectal cancer data
9d ago
EXEL
Exelixis price target raised to $41 from $38 at Oppenheimer
PremiumThe Fly
Exelixis price target raised to $41 from $38 at Oppenheimer
15d ago
EXEL
Exelixis price target raised to $42 from $38 at Truist
PremiumThe Fly
Exelixis price target raised to $42 from $38 at Truist
16d ago
EXEL
Exelixis price target raised to $41 from $34 at JMP Securities
PremiumThe Fly
Exelixis price target raised to $41 from $34 at JMP Securities
16d ago
EXEL
Exelixis price target raised to $37 from $36 at Piper Sandler
PremiumThe Fly
Exelixis price target raised to $37 from $36 at Piper Sandler
18d ago
EXEL
Exelixis reports preliminary FY24 revenue $2.165B, consensus $2.16B
PremiumThe FlyExelixis reports preliminary FY24 revenue $2.165B, consensus $2.16B
18d ago
EXEL
Exelixis price target raised to $40 from $29 at H.C. Wainwright
Premium
The Fly
Exelixis price target raised to $40 from $29 at H.C. Wainwright
21d ago
EXEL
No FDA advisory meeting for Exelixis a positive, says Citi
Premium
The Fly
No FDA advisory meeting for Exelixis a positive, says Citi
22d ago
EXEL
Exelixis says cabozantinib sNDA no longer Advisory Committee discussion subject
PremiumThe Fly
Exelixis says cabozantinib sNDA no longer Advisory Committee discussion subject
22d ago
EXEL
Exelixis price target raised to $42 from $33 at Guggenheim
PremiumThe Fly
Exelixis price target raised to $42 from $33 at Guggenheim
24d ago
EXEL
Exelixis price target raised to $38 from $34 at RBC Capital
PremiumThe Fly
Exelixis price target raised to $38 from $34 at RBC Capital
1M ago
EXEL
Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls
PremiumThe Fly
Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls
1M ago
WY
DHR
Brookline starts Exelixis with Buy on commercial drugs, pipeline
PremiumThe FlyBrookline starts Exelixis with Buy on commercial drugs, pipeline
1M ago
EXEL
Exelixis initiated with a Buy at Brookline
Premium
The Fly
Exelixis initiated with a Buy at Brookline
1M ago
EXEL
Exelixis downgraded to Market Perform from Outperform at BMO Capital
Premium
The Fly
Exelixis downgraded to Market Perform from Outperform at BMO Capital
1M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >